Lineage Cell Therapeutics, Inc. (LCTX)
Company Info
Highlights
$156.65M
-$0.07
$9.56M
$9.29M
-$20.89M
$0.37 - $1.15
$3.92
23.42%
32.66
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
Lineage Cell Therapeutics, Inc. (LCTX) returned 31.34% year-to-date (YTD) and -33.25% over the past 12 months. Over the past 10 years, LCTX returned -16.25% annually, underperforming the S&P 500 benchmark at 10.85%.
LCTX
31.34%
32.00%
15.40%
-33.25%
-19.18%
-5.63%
-16.25%
^GSPC (Benchmark)
0.51%
6.15%
-2.00%
12.92%
12.68%
14.19%
10.85%
Monthly Returns
The table below presents the monthly returns of LCTX, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 19.54% | -6.53% | -19.57% | 10.72% | 32.00% | 31.34% | |||||||
| 2024 | -14.67% | 11.82% | 42.31% | -26.35% | -8.26% | -0.27% | 3.28% | -14.18% | 2.42% | -8.17% | -31.20% | -12.13% | -53.90% |
| 2023 | 24.79% | -7.53% | 11.11% | -9.33% | -7.35% | 11.90% | 8.51% | -13.73% | -10.61% | -3.39% | -13.86% | 11.00% | -6.84% |
| 2022 | -35.51% | -10.76% | 9.22% | -20.78% | 2.46% | 26.40% | 3.80% | -14.02% | -19.86% | 22.12% | 5.07% | -19.31% | -52.24% |
| 2021 | 25.57% | 4.07% | 2.17% | 16.60% | -13.50% | 20.25% | -7.72% | -4.18% | 0.00% | -9.52% | -0.88% | 8.41% | 39.20% |
| 2020 | 15.73% | -1.94% | -18.01% | 2.64% | 3.73% | -1.33% | -5.75% | 11.59% | 2.36% | 17.45% | 30.00% | 23.08% | 97.75% |
| 2019 | 54.44% | -14.89% | 9.17% | -5.34% | -20.16% | 11.11% | 0.00% | -15.05% | 4.88% | -20.41% | 15.38% | -1.11% | -2.52% |
| 2018 | 35.35% | -9.97% | 2.67% | -19.70% | 3.70% | -8.04% | 26.21% | 5.77% | -14.55% | -17.02% | -21.06% | -36.15% | -54.29% |
| 2017 | -13.29% | 3.83% | 6.15% | -1.45% | -11.47% | 4.65% | -14.29% | 8.52% | -3.07% | -15.50% | 11.67% | -19.78% | -40.44% |
| 2016 | -36.11% | -4.96% | 24.78% | 1.74% | -2.06% | -8.74% | 19.54% | -5.77% | 32.65% | -17.43% | -2.18% | 14.60% | -4.69% |
| 2015 | 9.39% | 2.94% | 18.33% | 3.22% | -8.77% | -22.44% | -12.95% | -4.43% | -0.66% | 25.66% | -6.63% | 16.48% | 9.92% |
| 2014 | 3.33% | -3.49% | -8.36% | -21.27% | 11.58% | 5.54% | -16.72% | 22.44% | 0.96% | 7.96% | -5.02% | 15.84% | 3.61% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of LCTX is 31, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Lineage Cell Therapeutics, Inc. (LCTX) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the Lineage Cell Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Lineage Cell Therapeutics, Inc. was 95.36%, occurring on Apr 8, 2025. The portfolio has not yet recovered.
The current Lineage Cell Therapeutics, Inc. drawdown is 92.06%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -95.36% | Dec 28, 2010 | 3592 | Apr 8, 2025 | — | — | — |
| -64% | Apr 27, 2007 | 89 | Sep 17, 2007 | 203 | Aug 4, 2008 | 292 |
| -60.65% | Jan 30, 2006 | 135 | Aug 28, 2006 | 62 | Dec 4, 2006 | 197 |
| -48.33% | Apr 30, 2010 | 85 | Aug 30, 2010 | 65 | Dec 1, 2010 | 150 |
| -47.38% | Nov 10, 2005 | 30 | Dec 22, 2005 | 21 | Jan 25, 2006 | 51 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Lineage Cell Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Lineage Cell Therapeutics, Inc., comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 28.6% positive surprise.
Valuation
The Valuation section provides an overview of how Lineage Cell Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for LCTX relative to other companies in the Biotechnology industry. Currently, LCTX has a P/S ratio of 16.4. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for LCTX in comparison with other companies in the Biotechnology industry. Currently, LCTX has a P/B value of 1.9. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |